E. L. Pritchett

New drug application strategies for supraventricular arrhythmias

W. Wilkinson, E. L. Pritchett, 1991, Clinical pharmacology and therapeutics.

Modeling Recurrent Arrhythmias

W. Wilkinson, E. Pritchett, E. L. Pritchett, 2001, Journal of cardiovascular electrophysiology.

PHARMACOKINETIC STUDIES: THEIR ROLE IN DETERMINING THERAPEUTIC EFFICACY OF AGENTS DESIGNED TO PREVENT SUDDEN DEATH *

G. Wagner, S. Hammill, D. Shand, 1982, Annals of the New York Academy of Sciences.

Pharmacokinetic and pharmacodynamic effects of diltiazem.

E. Pritchett, D. Shand, B. R. Brown, 1983, The American journal of cardiology.

The method of separate exponentials: A simple aid to devising intravenous drug‐loading regimens

E. Pritchett, S. Hammill, T. Bjornsson, 1981, Clinical pharmacology and therapeutics.

Cost effectiveness of inpatient initiation of antiarrhythmic therapy for supraventricular tachycardias.

L. Shaw, D. Mark, E. Pritchett, 1997, The American journal of cardiology.

Antiarrhythmic effects of azimilide in atrial fibrillation: efficacy and dose-response. Azimilide Supraventricular Arrhythmia Program 3 (SVA-3) Investigators.

S. Connolly, R. Page, W. Wilkinson, 2000, Journal of the American College of Cardiology.

Dose-response relations of azimilide in the management of symptomatic, recurrent, atrial fibrillation.

S. Connolly, R. Page, W. Wilkinson, 2001, The American journal of cardiology.

Life-table methods for evaluating antiarrhythmic drug efficacy in patients with paroxysmal atrial tachycardia.

K. Lee, E. Pritchett, S. Hammill, 1983, The American journal of cardiology.